Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. tumourprint

TUMOURPRINT SIGNED

High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 TUMOURPRINT project word cloud

Explore the words cloud of the TUMOURPRINT project. It provides you a very rough idea of what is the project "TUMOURPRINT" about.

generations    rates    human    constitutes    commercialise    fold    global    ethically    animal    mimicking    candidates    proposition    trials    economic    reproducible    optimal    pharmaceutical    proper    designed    fabricating    2016    outcomes    bioprinters    market    universal    rely    microenvironment    secured    formulated    drive    collaborations    18    countries    bioinks    unsatisfactory    unparalleled    ing    specially    precise    capacity    mono    cultures    record    models    pay    grown    serial    robotics    hydrogels    failed    commercialising    humans    3d    ten    tumourprint    completely    offers    principally    fidel    revolutionise    commercialised    organisation    track    cellink    platform    analytical    cell    printed    exasperatingly    tissue    predict    giants    heterogeneity    disruptive    constructs    2d    successfully    company    proven    vascularity    size    automated    cancer    cells    producing    combination    establishment    scoring    bioink    survival    bioprinting    attrition    none    clinical    instructive    oncology    tumour    environment    commercialized    implications    live    world    first    willingness    throughput    printing    destructive    drug   

Project "TUMOURPRINT" data sheet

The following table provides information about the project.

Coordinator		 CELLINK AB 

Organization address
address: ARVID WALLGRENS BACKE 20
city: GOTEBORG
postcode: 413 46
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Project website https://cellink.com/global/
 Total cost 3˙500˙467 €
 EC max contribution 2˙450˙327 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2021-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLINK AB SE (GOTEBORG) coordinator 2˙450˙327.00

Map

 Project objective

CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical drug development and large-scale cancer research. Bioprinting constitutes the most advanced method for fabricating fidel tissue models, using live cells in combination with cell-instructive bioinks (specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development).

The high throughput platform - completely new to the market - is designed according to user needs. It will revolutionise drug development processes through serial production of fidel cancer models in an automated, precise and reproducible way. The platform offers unparalleled printing capacity and is integrated with robotics and none-destructive analytical methods capable of scoring drug responses in printed constructs.

Current oncology approaches principally rely on unsatisfactory 2D mono-cell cultures and animal models to predict outcomes in humans, resulting in exasperatingly high attrition rates of cancer drug candidates in clinical trials. The economic and ethically challenging implications of failed trials provide CELLINK with a unique value proposition to drive willingness-to-pay for their disruptive platform. TumourPrint will address today’s pharmaceutical challenges by producing tumour models capable of mimicking size, heterogeneity and vascularity of the human tumour microenvironment in a fidel way.

CELLINK has a proven track-record of successfully developing and commercialising products according to user needs; they developed the world’s first universal bioink, have commercialized three generations of bioprinters and optimised 18 cell-specific bioinks. Since the company’s establishment in 2016, CELLINK has commercialised its technology in over 40 countries, grown its organisation ten-fold and secured collaborations with several global pharmaceutical giants.

 Deliverables

List of deliverables.
Cancer cell lines selected Documents, reports 2019-11-28 17:30:38
10 hired employees Demonstrators, pilots, prototypes 2019-11-28 17:30:39

Take a look to the deliverables list in detail:  detailed list of TUMOURPRINT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUMOURPRINT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TUMOURPRINT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More